

<b>Reference:</b>	FOI.2138.19
<b>Subject:</b>	Oncology treatments
<b>Date of Request:</b>	25 November 2019

**Requested:**

1. Within your health trust how many patients are currently [within the past 3 months] being treated with the following for breast cancer?:

- Abemaciclib + aromatase inhibitor \*
- Abemaciclib + Fulvestrant
- Alpelisib + Fulvestrant
- Atezolizumab
- Bevacizumab
- Eribulin
- Everolimus + Exemestane
- Fulvestrant as a single agent
- Gemcitabine + paclitaxel
- Lapatinib
- Neratinib
- Olaparib
- Palbociclib + aromatase inhibitor\*
- Pertuzumab + trastuzumab + docetaxel
- Ribociclib + aromatase inhibitor\*
- Ribociclib + Fulvestrant
- Talazoparib
- Herceptin SC
- Herceptin IV
- Transtuzumab biosimilar SC
- Transtuzumab biosimilar IV
- Trastuzumab emtansine
- Other active systemic anti-cancer therapy \*\*

\*aromatase inhibitor eg. Anastrozole, Exemestane or Letrozole

\*\*eg. docetaxel, vinorelbine or capecitabine as a single agent

2. How many patients are being treated for:

2a. Neo-adjuvant breast cancer;

- Transtuzumab total SC
- Transtuzumab total IV

2b. Adjuvant breast cancer;

- Transtuzumab total SC
- Transtuzumab total IV

3. In the past 3 months, how many Urothelial cancer patients were treated with:

- Atezolizumab
- Carboplatinum in combination with another agent
- Carboplatinum single agent
- Cisplatinum in combination with another agent

Cisplatinum single agent  
Nivolumab  
Pembrolizumab  
Any other chemo regimen without cisplatinum or carboplatinum  
Other active systemic anti-cancer therapy [please state]  
Palliative care only

**Response:**

Hywel Dda University Health Board (UHB) is unable to provide you with the information requested as it is estimated that the cost of answering your request would exceed the “appropriate level” as stated in the Freedom of Information (Fees and Appropriate Limit) Regulations 2004. The “appropriate level” represents the estimated cost of one person spending 18 hours or (2 ½ working days) in determining whether the UHB holds the information, and locating, retrieving and extracting the information.

The ChemoCare team, who hold a central record of cancer treatments, is based within Swansea Bay University Health Board (SBUHB). In order to provide you with the information requested, the UHB would be required to conduct a manual trawl of all cancer patients’ medical records to establish the type of cancer diagnosed and therapies used to treat the patients. It is estimated that conducting this search would take longer than the 18 hour ‘appropriate limit’ as stated within the Act.

The UHB is therefore applying an exemption under Section 12 of the Freedom of Information Act 2000, which provides an exemption from a public authority’s obligation to comply with a request for information where the cost of compliance is estimated to exceed the *appropriate limit*.

Under section 16 of the Freedom of Information Act, the UHB has an obligation to provide advice and assistance.

We would therefore recommend that you redirect your request to the Freedom of Information Team in SBUHB who may be able to help you with your enquiry: -

[FOIA.Requests@wales.nhs.uk](mailto:FOIA.Requests@wales.nhs.uk) or alternatively, you can contact: FOIA Team, Swansea Bay University Health Board, Health Board Headquarters, 1 Talbot Gateway, Port Talbot, SA12 7BR.